Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate sites of gut absorption of BMS-986165 in males
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Formulation A | Experimental | Dosage formulation and area of release varies between arms |
|
| Formulation B | Experimental | Dosage formulation and area of release varies between arms |
|
| Formulation C | Experimental | Dosage formulation and area of release varies between arms |
|
| Formulation D | Experimental | Dosage formulation and area of release varies between arms |
|
| Formulation E | Experimental | Dosage formulation and area of release varies between arms |
|
| Formulation F | Experimental | Dosage formulation and area of release varies between arms |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BMS-986165 | Drug | Oral administration |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum observed plasma concentration (Cmax) of BMS-986165 following Treatments A, B, C, and D | Determined over 5 days | |
| Time of maximum observed plasma concentration (Tmax) of BMS-986165 following Treatments A, B, C, and D | Determined over 5 days | |
| Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986165 following Treatments A, B, C, and D | Determined over 5 days | |
| Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986165 following Treatments A, B, C, and D | Determined over 5 days | |
| Apparent plasma elimination half-life (T-HALF) of BMS-986165 following Treatments A, B, C, and D | Determined over 5 days |
| Measure | Description | Time Frame |
|---|---|---|
| Vital signs of body temperature | Up to 60 days | |
| Pulse rate | Up to 60 days | |
| Physical examination |
Not provided
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Scintipharma | Lexington | Kentucky | 40504 | United States |
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trial Information | View source |
| BMS Clinical Trial Patient Recruiting | View source |
| Investigator Inquiry Form |
Not provided
Not provided
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000628674 | deucravacitinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Formulation G | Experimental | Dosage formulation and area of release varies between arms |
|
| Formulation H | Experimental | Dosage formulation and area of release varies between arms |
|
| Up to 60 days |
| Incidence of adverse events (AE) | Up to 90 days |
| Incidence of serious adverse events (SAE) | Up to 90 days |
| Vital sign of respiratory rate | Up to 60 days |
| Vital sign of supine blood pressure | Up to 60 days |
| FDA Safety Alerts and Recalls | View source |